Wir sind mit live! Mehr erfahren

Elanco Animal Health

ELAN

Börsenwert 11,8 Mrd. $

23,55 USD

+0,01

0,04 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

23,02

-0,53

2,25 %

1 Tag

0,04 %

5 Tage

2,93 %

1 Monat

3,02 %

3 Monate

-9,25 %

6 Monate

1,82 %

Seit Jahresbeginn

4,57 %

1 Jahr

14,77 %

5 Jahre

-26,64 %

10 Jahre

-34,58 %

Profil: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.

Mitarbeiter: 9.900

Gesundheitswesen Arzneimittelhersteller – Spezialpräparate und Generika

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 40,7 %

Neutral 59,3 %

Negativ 0 %

What Growing Up on a Farm Taught Elanco's CEO

One of Jeff Simmons' pivotal leadership lessons came when he was 7 years old. Now CEO of Elanco Animal Health, Simmons said his family's upstate New York grape farm had been devastated by a hailstorm. It was the first time he saw his father cry.

What Growing Up on a Farm Taught Elanco's CEO

Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground

Elanco Animal Health NYSE: ELAN President and CEO Jeff Simmons outlined the company's growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London.

Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground

Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Elanco to Participate in BofA Securities Global Healthcare Conference 2026

INDIANAPOLIS, Sept. 17, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026.

Elanco to Participate in BofA Securities Global Healthcare Conference 2026

Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care

Innovation that protects against these pests is driving stronger Elanco base business and overall share gains. Elanco confirms U.S. Pet Health is on track to expectations of high-single digit to low double-digit growth in the second half of 2026.

Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care

Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement

INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026.

Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement

Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

INDIANAPOLIS, Sept. 10, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.

Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

The Motley Fool

Elanco Director Purchases 40,000 Shares for $936,000

The purchase was valued at $936,000. This investment increased the insider's direct equity position by 27%.

Elanco Director Purchases 40,000 Shares for $936,000

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens Elanco's leadership in the biologics space.

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt